Search
Takeda Pharmaceutical Co Ltd
TAKAdd to Watchlist
16.835USD
-0.035-0.21%
Close 07-23 16:00（ET）Quotes delayed by 15 min
53.19BMarket Cap
43.89P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-23The current earnings forecast score of Takeda Pharmaceutical Co Ltd is 8.67, ranking 12 out of 155 in the Pharmaceuticals industry. The average price target is 18.00, with a high of 19.30 and a low of 17.00.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
21.133
Target Price
+22.65%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Takeda Pharmaceutical Co Ltd
TAK
3
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Takeda Pharmaceutical Co Ltd's expected revenue for the next quarter?
Takeda Pharmaceutical Co Ltd's expected revenue is 7.19B.
What is Takeda Pharmaceutical Co Ltd's price target?
Analysts forecast that Takeda Pharmaceutical Co Ltd's price target is USD 18.00, with the highest forecast at USD 19.30 and the lowest forecast at USD 17.00.
How have Takeda Pharmaceutical Co LtdTAK's recent earnings per share performed?
The market expectation was USD -0.74, while Takeda Pharmaceutical Co LtdTAK's earnings per share (EPS) for the previous quarter was USD 0.21. EPS for the next quarter is expected at USD 0.86.
What is the analyst rating for Takeda Pharmaceutical Co Ltd?
Based on the ratings of Takeda Pharmaceutical Co Ltd's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.